Hans Trees

* Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMD * Positive recommendation is based on data from the LADDER, Archway and Portal studies showing Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections(1-3) * By continuously delivering medicine into the eye through the Contivue(®) refillable implant, Susvimo may help people with nAMD maintain their vision with as few as two treatments...

* The new test enables clinicians to reliably diagnose HDV and monitor patients' treatment response. * Hepatitis D affects nearly 12 million of people globally and is considered the most aggressive form of viral hepatitis, often leading to liver failure and cancer faster than other types.

* The Elecsys IGRA TB test expands global access to tuberculosis infection testing, advancing progress toward the World Health Organization's elimination targets. * Performed on Roche's industry-leading and widely available cobas immunoassay systems, the test enables laboratories to meet growing tuberculosis infection testing needs by reducing reliance on manual workflows through automation and digital solutions.